Literature DB >> 23397983

Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening.

M Krajc1, V Zadnik, S Novaković, V Stegel, E Teugels, N Bešič, M Hočevar, A Vakselj, J De Grève, J Zgajnar.   

Abstract

Knowledge of the geographical distribution of highly recurrent mutations may be useful for efficient screening in cancer families. Since the cloning of the BRCA1/2 genes, it is known that the wide spectrum of deleterious mutations shows high ethnic and geographic heterogeneity. In this study, we have tested probands from 582 breast/ovarian cancer families and positioned all 156 BRCA1/2 families on the map according to the family origin. We observed that high-risk families with the same recurrent mutation present a typical geographical distribution and that different recurrent mutations may show different distribution patterns. We then evaluated the genetic screening implications of this heterogeneous prevalence of the most recurrent mutations found [300T>G(c.181T>G), 1806C>T(c.1687C>T), 969ins7(c.844_850dupTCATTAC), 5382insC(c.5266dupC), 235G>A(c.116G>A) in BRCA1 and IVS16-2A>G(c.7806-2A>G) in BRCA2]. On the basis of these results, specific testing procedures for new incident cases may be offered according to their family origins and, according to the information regarding clusters revealed in this study, the individuals (especially those at low risk), originating from regions with clusters, might be screened preferentially for cluster mutations and analysis may be simplified according to the family origin.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRCA1; BRCA2; Slovenia; genetic testing; geographical distribution; recurrent mutations

Mesh:

Year:  2013        PMID: 23397983     DOI: 10.1111/cge.12119

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.

Authors:  Ana Krivokuca; Vita Setrajcic Dragos; Ljiljana Stamatovic; Ana Blatnik; Ivana Boljevic; Vida Stegel; Jelena Rakobradovic; Petra Skerl; Stevo Jovandic; Mateja Krajc; Mirjana Brankovic Magic; Srdjan Novakovic
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

2.  Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.

Authors:  Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik
Journal:  Breast Cancer Res Treat       Date:  2021-04-23       Impact factor: 4.872

Review 3.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

4.  Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.

Authors:  Giulia Cini; Massimo Mezzavilla; Lara Della Puppa; Elisa Cupelli; Alessio Fornasin; Angela Valentina D'Elia; Riccardo Dolcetti; Giuseppe Damante; Sara Bertok; Gianmaria Miolo; Roberta Maestro; Paolo de Paoli; Antonio Amoroso; Alessandra Viel
Journal:  BMC Med Genet       Date:  2016-02-06       Impact factor: 2.103

5.  Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.

Authors:  Mirjam Cvelbar; Marko Hocevar; Srdjan Novakovic; Vida Stegel; Andraz Perhavec; Mateja Krajc
Journal:  Radiol Oncol       Date:  2017-03-16       Impact factor: 2.991

6.  Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.

Authors:  Joaira Bakkach; Mohamed Mansouri; Touria Derkaoui; Ali Loudiyi; ElMostafa El Fahime; Amina Barakat; Naima Ghailani Nourouti; Jaime Martinez De Villarreal; Carlos Cortijo Bringas; Mohcine Bennani Mechita
Journal:  BMC Cancer       Date:  2020-09-07       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.